Overview

* TherapeuticsMD ( TXMD ) reports Q3 net income from cont ops of $50,000 compared to loss of $567,000 last year

* License revenue for Q3 rises due to changes in sales of licensed products

* Company exploring strategic alternatives, no assurance of transaction outcome

Outlook

* TherapeuticsMD ( TXMD ) is evaluating strategic alternatives, including mergers or asset sales

* Company has not set a timetable for strategic evaluations

Result Drivers

* LICENSE REVENUE INCREASE - License revenue rose due to changes in sales of licensed products

* OPERATING EXPENSES - Operating expenses decreased by 2.1% compared to Q3 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net $50,000

Income

from

Cont Ops

Q3 $1.65

Operatin mln

g

Expenses

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)